$CELC

Celcuity Inc. (CELC) reported updated Phase 1b/2 study results for gedatolisib in mCRPC patients. 82.2% of abiraterone-pretreated patients had no progression at six months. Median rPFS was 15.7 months. Phase 2 study expected in 2027.

Analysts made several calls on Wall Street, including upgrades for Block (SQ), Tesla (TSLA), and IBM (IBM), among others. BMO upgraded Block to outperform, citing positive catalysts. Morgan Stanley raised Tesla's price target to $410. Goldman Sachs reiterated IBM as a buy. Other notable mentions include upgrades for Kohl's (KSS) and downgrades for Netflix (NFLX).

Cantor Fitzgerald initiated coverage of Celcuity with an Overweight rating and $140 price target, implying 127.4% upside from the Oct 21 close. Analysts cite strong market potential and encouraging clinical data for gedatolisib (Revtorpyk), projecting peak sales of $2.7B for second-line treatment and $1.6B for first-line breast cancer.

TD Cowen raised its price target for Celcuity Inc. (NASDAQ:CELC) to $145, citing strong early uptake of its cancer treatment. The stock is down 52% over six months. Analysts' targets range from $134 to $177. Celcuity's market cap is $2.94 billion. Other analysts also raised targets, citing the company's drug pricing and potential. The company expects to launch Revtorpyk in late Q3 2026.

Celcuity (CELC) launched REVTORPYK in the US for certain breast cancer patients and filed an FDA application to expand its use. The company is investing in access infrastructure, and investors will watch early prescription trends and FDA review progress. Celcuity's consensus revenue and earnings forecasts for 2029 are US$817.9 million and US$267.5 million, respectively, up from current losses. The appointment of David W. Gryska to the board may impact financial oversight and execution.

Celcuity Inc. (CELC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Celcuity Appoints David Gryska To Its Board Of Directors Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board MINNEAPOLIS, October 2, 2026 — Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and comm

Celcuity Inc. (CELC) has added David W. Gryska to its Board of Directors, a move coinciding with its transition to the commercial stage following FDA approval of its drug REVTORPYK.

Celcuity (CELC) stock rose 2.8% on Wednesday, outperforming the S&P 500's 0.3% decline, as it launched its first FDA-approved product, Revtorpyk, for certain breast cancer treatments. The company also introduced support services for patients and physicians. Revtorpyk targets HR+/HER2 breast cancer, which accounts for 70% of cases.

Celcuity Inc. (CELC) announced that REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer patients without a PIK3CA mutation. The FDA approved REVTORPYK in July 2026 for use in combination with palbociclib and fulvestrant, or fulvestrant alone. The company also launched a support program for patient access and financial assistance.

Celcuity (CELC) reported a net loss of $78.9M in Q2 2026, up from $45.3M in Q2 2025, due to commercial expansion. The company submitted an sNDA for REVTORPYK in HR+/HER2- breast cancer with PIK3CA mutation, following its initial approval. The drug showed superior efficacy in trials, with a median PFS of 11.1 months compared to 5.6 months for the standard treatment. Celcuity has $754M in cash but faces high short interest and debt concerns.